Table 2 International Classification of Retinoblastoma and Prediction of outcomes of surgery
From: Retinoblastoma: present scenario and future challenges
Groups | Criterion | Number of Patients in group based on the study [49] n = 249 | Treatment and success rate |
|---|---|---|---|
Group A | Retinoblastoma tumor with size <  = 3 mm. | 23 (9%) | Chemo reduction with vincristine, etoposide and carboplatin for 6 cycles (CRD) plus thermotherapy or cryotherapy. 100% |
Group B | RB tumor with size > 3 mm, has a location close to the macula or presents with small amount of subretinal fluid. | 96 (39%) | CRD plus thermotherapy or cryotherapy. 93% |
Group C | Eyes with localised seeding of the tumor. | 21 (8%) | CRD plus thermotherapy or cryotherapy. 90% |
Group D | Diffuse seeding of the tumor within the eyes. | 109 (44%) | CRD plus thermotherapy or cryotherapy. 47% |
Group E | Huge mass of the tumor covering a great proportion of the eye. | 0 as the patients needed management with enucleation and hence were excluded from the study. | Enucleation with CRD in certain cases. |